Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival-Reference-Cited by-同舟云学术

Programmed Cell Death Ligand-1 (PD-L1) and CD8 Expression Profiling Identify an Immunologic Subtype of Pancreatic Ductal Adenocarcinomas with Favorable Survival

Published:2019-05-01 Issue:6 Volume:7 Page:886-895
ISSN:2326-6066
Container-title:Cancer Immunology Research
language:en
Short-container-title:Cancer Immunol Res

Author:

Danilova Ludmila^ORCID,Ho Won Jin,Zhu Qingfeng,Vithayathil Teena,De Jesus-Acosta Ana^ORCID,Azad Nilofer S.,Laheru Daniel A.,Fertig Elana J.,Anders Robert,Jaffee Elizabeth M.,Yarchoan Mark

Funder

HHS | NIH | National Cancer InstituteHHS | NIH | National Cancer Institute (NCI)

HHS | National Institutes of HealthHHS | National Institutes of Health (NIH)

The Viragh Foundation

Publisher

American Association for Cancer Research (AACR)

Subject

Cancer Research,Immunology

Cited by 191 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. SLC4A4 as a novel biomarker involved in immune system response and lung adenocarcinoma progression;International Immunopharmacology;2024-10

2. Comprehensive pan-cancer analysis of ZNF337 as a potential diagnostic, immunological, and prognostic biomarker;BMC Cancer;2024-08-09

3. Focus on Pancreatic Cancer Microenvironment;Current Oncology;2024-07-26

4. Scinderin is a potential prognostic biomarker and correlated with immunological regulation: from pan-cancer analysis to liver hepatocellular carcinoma;Frontiers in Immunology;2024-07-23

5. Identification of Stem Cell-related Gene Markers by Comprehensive Transcriptome Analysis to Predict the Prognosis and Immunotherapy of Lung Adenocarcinoma;Current Stem Cell Research & Therapy;2024-07